Skip to content
ADMETatlas
peptide evidence atlas
Home
About
Home

Browse

PeptidesProductsEvidenceContext signalsDescriptors

Developability

ProfileComparator

Resources

ManualExplanationsStatisticsDownloadLicenseAbout
  1. Home
  2. Peptides
  3. Ganirelix
Peptide·plain sequence-like

Ganirelix

ATLPC0014068

Routes
Compare in workbenchDownload releaseAPI JSON
On this page
  • 01 Sequence & molecular identity
  • 02 Physicochemical profile
  • 03 Exposure / Absorption
  • 04 Distribution / Barrier
  • 05 Excretion / Persistence
  • 06 Evidence landscape
  • 07 Product context
  • 08 Identity & reference map
  • 09 Data access & reproducibility
Coveragecounts only · not riskATLPC0014068
  • Measurements
    10
  • Endpoints
    7
  • Domains
    3/5
  • Products
    1
  • No matrix stability evidence
  • 2 clearance measurements
  • Product-level review pending
  • No sequence liability cues
Jump to domain

Open the matching evidence section below

All evidence index · 10
Exposure / Absorption
6 measurements
Distribution / Barrier
2 measurements
Metabolic & Proteolytic Stability
No evidence
Excretion / Persistence
2 measurements
Toxicity / Safety
No evidence
01

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

No reviewed sequence representation available

This peptide currently has identity-level evidence, but no reviewed sequence, HELM, or SMILES representation for residue-level interpretation.

Structure & chemistry

·
Chemical representationnone
Representation class

How the current release can interpret this identity chemically.

plain sequence-like
Parent-residue sequence

Residue string used for positional interpretation when available.

Not available
HELM

Polymer notation for modified peptide representation when available.

Not available
SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available
No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached
3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modificationsnone
Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

02

Physicochemical profile

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Physicochemical descriptors unavailable

These descriptors require a standard parent-residue sequence. The module remains visible so modified or unresolved identities are not forced into unreliable computed values.

03

Exposure / Absorption

6 records

What evidence describes systemic exposure or absorption?

Evidence records
6
Complete canonical measurements and observations attached to this domain.
Endpoint scope
4
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
0
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
6
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeCmaxAUCTmaxBioavailability
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
0
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
6
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Bioavailability1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

91.1 %

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: ATLPF0020957 · Route: subcutaneous · Ganirelix· Pharmacokinetics · bioavailability single percent · The mean absolute bioavail... · Source: Primary reference linked

Reference
AUC2 records · 0 matched-context · 2 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

77.1 ng*h/mL

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: ATLPF0020957 · Route: subcutaneous · Ganirelix· Pharmacokinetics · ganirelix table i auc0-24 multiple dose · TABLE I: Mean (SD... · Source: Primary reference linked

Reference
2

96 ng*h/mL

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: ATLPF0020957 · Route: subcutaneous · Ganirelix· Pharmacokinetics · ganirelix table i auc0-inf single dose · TABLE I: Mean (SD)... · Source: Primary reference linked

Reference
Cmax2 records · 0 matched-context · 2 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

11.2 ng/mL

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: ATLPF0020957 · Route: subcutaneous · Ganirelix· Pharmacokinetics · ganirelix table i cmax multiple dose · TABLE I: Mean (SD) p... · Source: Primary reference linked

Reference
2

14.8 ng/mL

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: ATLPF0020957 · Route: subcutaneous · Ganirelix· Pharmacokinetics · ganirelix table i cmax single dose · TABLE I: Mean (SD) pha... · Source: Primary reference linked

Reference
Tmax1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

~ 1 hour

~ 3600 seconds
Use only explicitly reported fields

human · serum

Result: Approximate quantitative measurement · Molecular form: ATLPF0020957 · Route: subcutaneous · Ganirelix· Pharmacokinetics · ganirelix tmax maximum serum concentration reached · multip... · Source: Primary reference linked

Reference
04

Distribution / Barrier

2 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records
2
Complete canonical measurements and observations attached to this domain.
Endpoint scope
2
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
0
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
2
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeVdPlasma protein binding
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
0
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
2
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Vd1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

43.7 L

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: ATLPF0020957 · Route: intravenous · Ganirelix· Pharmacokinetics · ganirelix volume of distribution iv mean sd · Distribution... · Source: Primary reference linked

Reference
Plasma protein binding1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

81.9 %

Use only explicitly reported fields

human · plasma

Result: Reported point value · Molecular form: ATLPF0020957 · Ganirelix· Pharmacokinetics · protein binding to human plasma percent · In vitro protein... · Source: Primary reference linked

Reference
Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA
0

artificial membrane

Caco-2
0

cell monolayer

MDCK
0

cell monolayer

RRCK
0

cell monolayer

BBB
0

barrier evidence

05

Excretion / Persistence

2 records

What evidence describes clearance or persistence?

Evidence records
2
Complete canonical measurements and observations attached to this domain.
Endpoint scope
1
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
0
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
2
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeClearance
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
0
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
2
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Clearance2 records · 0 matched-context · 2 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

3.3 L/h

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: ATLPF0020957 · Route: subcutaneous · Ganirelix· Pharmacokinetics · ganirelix table i cl f multiple dose · TABLE I: Mean (SD) p... · Source: Primary reference linked

Reference
2

2.4 L/h

Use only explicitly reported fields

human

Result: Reported point value · Molecular form: ATLPF0020957 · Route: subcutaneous · Ganirelix· Pharmacokinetics · ganirelix table i cl f single dose · TABLE I: Mean (SD) pha... · Source: Primary reference linked

Reference
06

Evidence landscape

10 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain
Eligible when context matches
Interpret as reported
Supporting context only
Review before analysis
Exposure / Absorption
6 evidence records
0
6
0
0
Distribution / Barrier
2 evidence records
0
2
0
0
Metabolic & Proteolytic Stability
0 evidence records
0
0
0
0
Excretion / Persistence
2 evidence records
0
2
0
0
Toxicity / Safety
0 evidence records
0
0
0
0
Endpoint distribution

Top evidence-bearing endpoint questions.

Area Under Curve
2
Clearance
2
Max Concentration
2
Bioavailability
1
Plasma Protein Binding
1
Time To Max Concentration
1
Volume Of Distribution
1
Assay context

Broad context buckets, useful before comparing values.

In vivo / route
10
Traceability

Reference-link availability for measurement-level audit.

Linked reference
10
Not linked
0
All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

#ADMET domainEndpointReported valueResult typeAnalysis useAssay / modelConditionReference
1
Exposure / Absorption
Exposure
Max Concentration
14.8 ng/mL
Reported point valueUse only explicitly reported fieldshumanRoute: subcutaneous · the table footnote states CL/F is based on intravenous administration.
Reference
Primary reference linked
2
Exposure / Absorption
Exposure
Area Under Curve
96 ng*h/mL
Reported point valueUse only explicitly reported fieldshumanRoute: subcutaneous · the table footnote states CL/F is based on intravenous administration.
Reference
Primary reference linked
3
Excretion / Persistence
Persistence
Clearance
2.4 L/h
Reported point valueUse only explicitly reported fieldshumanRoute: subcutaneous · the table footnote states CL/F is based on intravenous administration.
Reference
Primary reference linked
4
Exposure / Absorption
Exposure
Max Concentration
11.2 ng/mL
Reported point valueUse only explicitly reported fieldshumanRoute: subcutaneous
Reference
Primary reference linked
5
Exposure / Absorption
Exposure
Area Under Curve
77.1 ng*h/mL
Reported point valueUse only explicitly reported fieldshumanRoute: subcutaneous
Reference
Primary reference linked
6
Excretion / Persistence
Persistence
Clearance
3.3 L/h
Reported point valueUse only explicitly reported fieldshumanRoute: subcutaneous
Reference
Primary reference linked
7
Exposure / Absorption
Exposure
Time To Max Concentration
~ 1 hour
~ 3,600 seconds
Approximate quantitative measurementUse only explicitly reported fieldshuman · serumRoute: subcutaneous
Reference
Primary reference linked
8
Distribution / Barrier
Distribution
Volume Of Distribution
43.7 L
Reported point valueUse only explicitly reported fieldshumanRoute: intravenous
Reference
Primary reference linked
9
Exposure / Absorption
Exposure
Bioavailability
91.1 %
Reported point valueUse only explicitly reported fieldshumanRoute: subcutaneous
Reference
Primary reference linked
10
Distribution / Barrier
Distribution
Plasma Protein Binding
81.9 %
Reported point valueUse only explicitly reported fieldshuman · plasmaNot specified
Reference
Primary reference linked
1–10 / 10
07

Product context

1 products

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

·
Summary1 linked product
Linked products
1
Label context
None
Clinical trials
30
Safety label cues
None
Linked products1 shown

Ganirelix

Peptide-product match
Reviewed peptide match
Route / product class
subcutaneous · Injection, solution
Clinical context
30 trial records · 11 exact intervention matches · 6 with results · latest 2026-04-14
Label safety context
No label safety cue linked
View product
08

Identity & reference map

10 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

·
Summary1 reference group
Identity type
identity record
Reported notation
0
Reference groups
1
Measurements
10
ATL peptide ID
ATLPC0014068
Identity concordance
Identity concordance
Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 10
Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 10
Different notation

Reported notation does not resolve to the current display sequence.

0 / 10
Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

10 / 10
Reported sequence notation

No source-specific sequence notation has been captured in the current identity references.

Current identity
No sequence representation
Reported names
No distinct human-readable aliases are exposed.
Reference map1 reference group
Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

ReferenceSupportsReported identityRecords
Reference
Open
DistributionExposurePersistence
Area Under Curve, Bioavailability, Clearance, Max Concentration +3 more
No reported alias
10 identity
10 evidence
09

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

·
Record scopePublic release
ATL peptide ID
ATLPC0014068
Identity type
identity record
ADMET endpoints
7
Evidence records
10
Reference groups
1
Release view
Public release
Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements
Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint
GET /api/v1/peptides/ATLPC0014068
open
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0014068' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'
ADMETatlas
peptide evidence atlas

ADMETatlas is an open, curated atlas of ADMET evidence for therapeutic peptides — spanning developability, membrane permeability and blood–brain-barrier transport, immune-recognition context, and approved-product context. Every measurement stays linked to its original source, with stable identifiers and transparent curation, so results can be traced, cited, and reproduced.

Browse
PeptidesProductsEvidenceContext signalsDescriptors
Resource
DevelopabilityComparatorManualExplanationsStatisticsDownloadAbout
Stack
  • RDKit
  • Mol*
  • Python
  • FastAPI
  • PostgreSQL
  • Next.js
  • React
  • TypeScript
  • Tailwind CSS
  • Apache ECharts
© 2026 ADMETatlas, an academic peptide ADMET evidence atlas.